26 August 2019 | News
Funding will be used primarily to support Atonarp's product prototyping and commercialization in 2020 and beyond
Atonarp's Smart Mass Spectrometer
Atonarp, a Japan headquartered hi-tech molecular diagnostics company, has announced that it has raised $33 million in an oversubscribed Series C funding round.
This financing round has attracted five new investors including Japan Post Investment Corporation, SBI Investment Co., Ltd, and Northwestern Mutual Future Ventures as well as current investors, INCJ, Ltd, Innovative Venture Fund Investment Limited Partnership, and a major medical equipment manufacturing company.
Since early 2014, Atonarp has raised more than $61 million in three rounds of equity financing in pursuit of its vision of ushering in the next generation of process monitoring and healthcare diagnostics through its innovative AI-based platforms of mass spectrometry and optical spectroscopy. The latter is geared to deliver pain-free point-of-care blood testing with lab-quality accuracy but with real-time actionable data.
These unparalleled advantages are also expected to bring about cost savings to patients and healthcare providers. The Series C funding will grow the company's balance sheet and support ongoing product prototyping and commercialization into the healthcare market.